Relugolix structure
|
Common Name | Relugolix | ||
---|---|---|---|---|
CAS Number | 737789-87-6 | Molecular Weight | 623.63 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C29H27F2N7O5S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of RelugolixRelugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013.target: GnRH [1]IC50: 0.33 nM [1]In vivo: In female knock-in mice, twice-daily oral administration of TAK-385 (100mg/kg) induces constant diestrous phases within the first week, decreases the uterus weight to ovariectomized levels and downregulated GnRH receptor mRNA in the pituitary after 4 weeks.[2] |
Name | 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea |
---|---|
Synonym | More Synonyms |
Description | Relugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013.target: GnRH [1]IC50: 0.33 nM [1]In vivo: In female knock-in mice, twice-daily oral administration of TAK-385 (100mg/kg) induces constant diestrous phases within the first week, decreases the uterus weight to ovariectomized levels and downregulated GnRH receptor mRNA in the pituitary after 4 weeks.[2] |
---|---|
Related Catalog | |
References |
Molecular Formula | C29H27F2N7O5S |
---|---|
Molecular Weight | 623.63 |
PSA | 169.36000 |
LogP | 3.96660 |
Storage condition | 2-8℃ |
TAK-385 |
Relugolix |